ArticleScientific reports2019

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.

Bogdan Mitran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.